LIFEVANTAGE CORP Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent
LIFEVANTAGE CORP (LFVN) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent of -4.10% for the 12-month period ending 2026-06-30, per its 10-K filed 2026-08-27.
Financial Statements › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost · last filed 2026-08-27
- LIFEVANTAGE CORP effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, percent for fiscal 2026 was -4.10%.
- LIFEVANTAGE CORP effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, percent for fiscal 2025 was -6.20%.
- LIFEVANTAGE CORP effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, percent for fiscal 2024 was -8.30%.
- LIFEVANTAGE CORP effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, percent for fiscal 2023 was -5.80%.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent 12 month | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent 12 month as first filed |
|---|---|---|
| 2026-06-30 | -4.10% 10-K · filed 2026-08-27 | |
| 2025-06-30 | -6.20% 10-K · filed 2026-08-27 | |
| 2024-06-30 | -8.30% 10-K · filed 2025-09-04 | 8.30% 10-K · filed 2024-08-28 |
| 2023-06-30 | -5.80% 10-K · filed 2024-08-28 | |
| 2022-06-30 | -3.90% 10-K · filed 2023-08-28 | |
| 2021-06-30 | 2.30% 10-K · filed 2022-08-23 | |
| 2020-06-30 | 13.60% 10-K · filed 2022-08-23 | -13.60% 10-K · filed 2020-08-18 |
| 2019-06-30 | 7.70% 10-K · filed 2021-08-19 | -7.70% 10-K · filed 2019-08-14 |
| 2018-06-30 | 0.70% 10-K · filed 2020-08-18 | |
| 2017-06-30 | 4.60% 10-K · filed 2019-08-14 | |
| 2016-06-30 | 0.90% 10-K · filed 2018-08-15 | |
| 2015-06-30 | 1.20% 10-K · filed 2017-09-07 | |
| 2014-06-30 | 1.30% 10-K · filed 2016-12-12 | |
| 2013-06-30 | 0.80% 10-K · filed 2015-09-01 | 0.78% 10-K · filed 2013-09-12 |
| 2012-06-30 | 0.30% 10-K · filed 2014-09-10 | |
| 2011-06-30 | 0.21% 10-K · filed 2013-09-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |